Investors

Investor Relations

TFF Pharmaceuticals, Inc. is an early-stage biopharmaceutical company focused on the development and commercialization of new inhalation products for the treatment of chronic respiratory diseases and lung conditions.


In early testing the Thin Film Freezing (TFF) proprietary platform significantly improved the solubility of drugs that have poor water solubility.
 

Mar 10, 2021: TFF Pharmaceuticals Fourth Quarter and Full-Year 2020 Financial and Business Results Conference

 

TFF Pharmaceuticals Corporate Overview – March 2020


Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

TFF Pharmaceuticals Provides Update on Clinical Development Programs
March 4, 2021
Phase 1 clinical study report for Voriconazole Inhalation Powder indicated no treatment emergent adverse events at peak plasma levels for   Invasive Pulmonary Aspergillosis Phase 1 Single Ascending Dose study of Tacrolimus Inhalation Powder met and exceeded therapeutic drug levels with a single
Read More
TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)
February 19, 2021
Company’s Thin Film Freezing maintained efficacy for two different biodefense countermeasures against Alphaviruses and Filoviruses AUSTIN, Texas --(BUSINESS WIRE)--Feb. 19, 2021-- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and
Read More

Featured Presentation

More information is coming soon.

About

Management Board of Directors Fact Sheet

Science

The Problem The Solution Benefits

Products

Regulatory Pathway Initial Focus

More

Investors Contact

© 2021 TFF Pharmaceuticals, Inc.

All Rights Reserved.

Privacy Policy.
Top